Cargando…

Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington’s disease

BACKGROUND: Cell therapy is a potential therapeutic approach for several neurodegenetative disease, including Huntington Disease (HD). To evaluate the putative efficacy of cell therapy in HD, most studies have used excitotoxic animal models with only a few studies having been conducted in genetic an...

Descripción completa

Detalles Bibliográficos
Autores principales:	El-Akabawy, Gehan, Rattray, Ivan, Johansson, Saga M, Gale, Richard, Bates, Gillian, Modo, Michel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502570/ https://www.ncbi.nlm.nih.gov/pubmed/22876937 http://dx.doi.org/10.1186/1471-2202-13-97

Ejemplares similares

Correlations of Behavioral Deficits with Brain Pathology Assessed through Longitudinal MRI and Histopathology in the R6/1 Mouse Model of Huntington’s Disease
por: Rattray, Ivan, et al.
Publicado: (2013)

Correlations of Behavioral Deficits with Brain Pathology Assessed through Longitudinal MRI and Histopathology in the HdhQ150/Q150 Mouse Model of Huntington’s Disease
por: Rattray, Ivan, et al.
Publicado: (2017)

Ex vivo 100 μm isotropic diffusion MRI-based tractography of connectivity changes in the end-stage R6/2 mouse model of Huntington’s disease
por: Manivannan, Ashwinee, et al.
Publicado: (2023)

Correlations of Behavioral Deficits with Brain Pathology Assessed through Longitudinal MRI and Histopathology in the R6/2 Mouse Model of HD
por: Rattray, Ivan, et al.
Publicado: (2013)

Dysfunction of the CNS-Heart Axis in Mouse Models of Huntington's Disease
por: Mielcarek, Michal, et al.
Publicado: (2014)

The Ubiquitin-Proteasome Reporter GFPu Does Not Accumulate in Neurons of the R6/2 Transgenic Mouse Model of Huntington's Disease
por: Bett, John S., et al.
Publicado: (2009)

Dantrolene is neuroprotective in Huntington's disease transgenic mouse model
por: Chen, Xi, et al.
Publicado: (2011)

Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease
por: Vernon, Anthony C, et al.
Publicado: (2010)

Therapeutic Effect of Berberine on Huntington’s Disease Transgenic Mouse Model
por: Jiang, Wenxiao, et al.
Publicado: (2015)

Effects of excitotoxicity in the hypothalamus in transgenic mouse models of Huntington disease
por: Henningsen, Jo B., et al.
Publicado: (2021)

Evolution of Extra-Nigral Damage Predicts Behavioural Deficits in a Rat Proteasome Inhibitor Model of Parkinson's Disease
por: Vernon, Anthony C., et al.
Publicado: (2011)

Ataxic Symptoms in Huntington’s Disease Transgenic Mouse Model Are Alleviated by Chlorzoxazone
por: Egorova, Polina A., et al.
Publicado: (2020)

Embryonic Mutant Huntingtin Aggregate Formation in Mouse Models of Huntington’s Disease
por: Osmand, Alexander P., et al.
Publicado: (2016)

A Transgenic Mouse Line Expressing Cre Recombinase in Undifferentiated Postmitotic Mouse Retinal Bipolar Cell Precursors
por: Nickerson, Philip E. B., et al.
Publicado: (2011)

Circadian Abnormalities in Motor Activity in a BAC Transgenic Mouse Model of Huntington’s Disease
por: Oakeshott, Stephen, et al.
Publicado: (2011)

Genome-Wide Histone Acetylation Is Altered in a Transgenic Mouse Model of Huntington's Disease
por: McFarland, Karen N., et al.
Publicado: (2012)

Comparative Magnetic Resonance Imaging and Histopathological Correlates in Two SOD1 Transgenic Mouse Models of Amyotrophic Lateral Sclerosis
por: Caron, Ilaria, et al.
Publicado: (2015)

Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington's disease
por: Benn, Caroline L, et al.
Publicado: (2008)

Requirement of the 3′-UTR-dependent suppression of DAZL in oocytes for pre-implantation mouse development
por: Fukuda, Kurumi, et al.
Publicado: (2018)

Responses to Environmental Enrichment Differ with Sex and Genotype in a Transgenic Mouse Model of Huntington's Disease
por: Wood, Nigel I., et al.
Publicado: (2010)

Necrostatin-1 ameliorates symptoms in R6/2 transgenic mouse model of Huntington's disease
por: Zhu, S, et al.
Publicado: (2011)

Dysfunctional mitochondrial respiration in the striatum of the Huntington’s disease transgenic R6/2 mouse model
por: Aidt, Frederik Heurlin, et al.
Publicado: (2013)

CD200 is up-regulated in R6/1 transgenic mouse model of Huntington's disease
por: Comella Bolla, Andrea, et al.
Publicado: (2019)

Striatal Pre-Enkephalin Overexpression Improves Huntington’s Disease Symptoms in the R6/2 Mouse Model of Huntington’s Disease
por: Bissonnette, Stéphanie, et al.
Publicado: (2013)

The Huntington's Disease-Related Cardiomyopathy Prevents a Hypertrophic Response in the R6/2 Mouse Model
por: Mielcarek, Michal, et al.
Publicado: (2014)

Genetic Knock-Down of Hdac3 Does Not Modify Disease-Related Phenotypes in a Mouse Model of Huntington's Disease
por: Moumné, Lara, et al.
Publicado: (2012)

Lessons Learned from the Transgenic Huntington's Disease Rats
por: Vlamings, Rinske, et al.
Publicado: (2012)

Human neural stem cell-induced endothelial morphogenesis requires autocrine/paracrine and juxtacrine signaling
por: Chou, Chung-Hsing, et al.
Publicado: (2016)

Correction: Responses to Environmental Enrichment Differ with Sex and Genotype in a Transgenic Mouse Model of Huntington's Disease
por: Wood, Nigel I., et al.
Publicado: (2010)

A common gene expression signature in Huntington’s disease patient brain regions
por: Neueder, Andreas, et al.
Publicado: (2014)

Ablation of kynurenine 3-monooxygenase rescues plasma inflammatory cytokine levels in the R6/2 mouse model of Huntington’s disease
por: Bondulich, Marie Katrin, et al.
Publicado: (2021)

Hdac6 Knock-Out Increases Tubulin Acetylation but Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's Disease
por: Bobrowska, Anna, et al.
Publicado: (2011)

miR-196a Ameliorates Cytotoxicity and Cellular Phenotype in Transgenic Huntington’s Disease Monkey Neural Cells
por: Kunkanjanawan, Tanut, et al.
Publicado: (2016)

Inhibition of tumour necrosis factor alpha in the R6/2 mouse model of Huntington’s disease by etanercept treatment
por: Pido-Lopez, Jeffrey, et al.
Publicado: (2019)

Metabolic disruption identified in the Huntington’s disease transgenic sheep model
por: Handley, Renee. R., et al.
Publicado: (2016)

Transgenic animal models for study of the pathogenesis of Huntington’s disease and therapy
por: Chang, Renbao, et al.
Publicado: (2015)

Striatal Interneurons in Transgenic Nonhuman Primate Model of Huntington’s Disease
por: Lallani, Shoeb B., et al.
Publicado: (2019)

Prolonged day length exposure improves circadian deficits and survival in a transgenic mouse model of Huntington's disease
por: Ouk, Koliane, et al.
Publicado: (2016)

Formation of Polyglutamine Inclusions in a Wide Range of Non-CNS Tissues in the HdhQ150 Knock-In Mouse Model of Huntington's Disease
por: Moffitt, Hilary, et al.
Publicado: (2009)

Irritability in pre-clinical Huntington's disease
por: Klöppel, Stefan, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_94iat0uh1hcem5oh4vneemhh0f